Dilara SEÇKİN, Nevin İLHAN, Yılmaz ÖZBAY, Necip İLHAN

Koroner arter hastalığı ile anjiyotensinojen T207M ve faktör II, faktör V gen polimorfizmleri arasındaki ilişki

Anjiyotensinojen (AGT) T207M, faktör V ve faktör II gen polimorfizminin koroner arter hastalığı (KAH) riski ile ilişkisi birbiri ile çelişen sonuçlar ile birlikte birkaç çalışmada gösterilmiştir. Biz, koroner anjiyografi ile tanı konulmuş koroner arter hastalarında AGT T207M geni ve faktör II ile Faktör V polimorfizmlerini analiz ettik. Anjiyotensinojen gen polimorfizmi polimeraz zincir reaksiyonu ve agaroz jel elektroforez teknikleri ile, faktör II ve V polimorfizmleri ise real time PCR ile tespit edildi. Bizim sonuçlarımız, Anjiyotensinojen T207M, Faktör II ve V polimorfizmlerinin koroner arter hastalığı ile ilişkili olmadığını ortaya koymuştur.

Anahtar Kelimeler:

Anjiyotensinojen, Faktör V, Polimorfizm, genetik, Protrombin, Koroner arter hastalığı

Association between angiotensinogen T207M and factor II, factor V gene polymorphism with coronary artery disease

The relations of the angiotensinogen (AGT) T207M, Factor V and Factor II gene polymorphisms to the risk of coronary artery disease (CAD) have been investigated in only a few studies with conflicting results. We analysed the relationships of AGT T207M gene and Factor II and Factor V polymorphisms to CAD whose coronary anatomy was defined by means of coronary angiography. Polymerase Chain Reaction (PCR) and agarose gel electrophoresis tecniques were used to determine the Angiotensinogen gene and real time PCR were used to determine Factor V and II gene polymorphism. Our results indicate that the angiotensinogen T207M, Factor II and Factor V polymorphisms are not related to CAD.

Keywords:

Angiotensinogen, Factor V, Polymorphism, Genetic, Prothrombin, Coronary Artery Disease,

PDF

___

1. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest.1990; 86: 1343- 1346.
2. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S. et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641– 644.
3. Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the hypertension-associated Met235.Thr allele of the human angiotensinogen gene. Hum Mol Genet 1993; 2: 609–610.
4. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, et al. Association of angiotensinogen gene T235 variant with increased risk of coronary artery disease. Lancet 1995; 345: 1600–1603.
5. Ludwig EH, Borecki IB, Ellison RC, Folsom AR, Heiss G, Higgins M, et al. Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI family heart study. Ann Epidemiol 1997; 7: 3–12.
6. Ko YL, Ko YS, Wang SM, Chu PH, Teng MS, Cheng NJ, et al. Angiotensinogen and angiotensin I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. Hum Genet 1997; 100: 210–214.
7. Antonarakis SE Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998; 11: 1–3
8. Kunz R, Kreutz R, Beige J, Distler A, Sharma AM. Association between the angiotensinogen 235-T variant and essential hypertension in whites: a systematic review and methodological appraisal. Hypertension 1997; 30: 1331–1337
9. Jeunemaitre X, Gimenez-Roqueplo AP, Celerier J, Corvol P Angiotensinogen variants and human hypertension. Curr Hypertens Rep 1999; 1: 31–41
10. Wang JG, Staessen JA. Genetic polymorphisms in the reninangiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000; 410: 289–302
11. Ruddock V, Meade TW. Factor VII activity and ischemic heart disease: fatal and non-fatal events. Q J Med 1994; 87: 403–406.
12. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533–537.
13. De Boever E, De Bacquer D, Braeckman L, et al. Relation of fibrinogen to lifestyles and to cardiovascular risk factors in a working population. Int J Epidemiol. 1995; 24: 915–921.
14. Eliasson M. Asplund K, Evrin PE, Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic varables and serum insulin: the Northern Sweden MONICA study. Atherosclerosis 1995; 113: 41–53.
15. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997; 98: 353–355.
16. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998.; 338: 1793–1797.
17. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 1997; 43: 1678– 1683.
18. de Maat MPM, Green F, de Knijff P, Jespersen J, Kluft C. Factor VII polymorphisms in populations with different risk of cardiovascular disease. ArteriosclerThrombVasc Biol. 1997; 17: 1918–1923.
19. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332: 912–917.
20. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Sciencem 1989; 245: 186–8.
21. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327–31.
22. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cyomolgus monkeys. Cardiovasc Pharmacol 1990; 15(Suppl 15): S65–S72.
23. Wang DH, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 1990; 15: 68–77.
24. Tiret L, Ricard S, Poirier O, Arveiler D, Cambou JP, Luc G, et al. Genetic variation at the angiotensinogen locus in relation to high blood pressure and myocardial infarction. J Hypertens 1995;13:311–7.
25. Caulfield M, Lavender P, Newell-Price J, Farrall M, Kamdar S, Daniel H, et al. Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans. J. Clin. Invest. 1995; 96: 687–692.
26. Nair KG, Shalia KK, Ashavaid TF, Dalal JJ. Coronary Heart Disease, Hypertension, and Angiotensinogen Gene Variants in Indian Population. J Clin Lab Anal. 2003; 17: 141–146
27. Ko YL, Ko YS, Wang SM, Chu PH, Teng MS, Cheng NJ, et al. Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. Hum Genet 1997;100: 210–214
28. Gardemann A, Stricker J, Humme J, Nguyen Q , Katz N, Philipp M, et al. Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis. Atherosclerosis 1999; 145 309–314
29. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1–6
30. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an arg 506gln mutation in the gene for factor V (factor V leiden). N Engl J Med 1997; 336: 399–403.
31. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–67.
32. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
33. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21
34. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83: 822-825.
35. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998; 79: 912-915.
36. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100: 3-10.
37. Corral J, Gonzalez-Conejero R, Lozano ML, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 1997; 99: 304-307
38. Russo C, Girelli D, Olivieri O, Guarini P, Manzato F, Pizzolo F, et al. G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulation 2001; 103: 2436-40.
39. Coulet F, Godard V, Verdy E, Soubrier F. Lack of association of the prothrombin gene variant G20210A with myocardial infarction in Caucasian males. Thromb Haemost 2000; 83: 796-7.
40. Croft SA, Daly ME, Steeds RP, Channer KS, Samani NJ, Hampton KK. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost 1999; 81: 861-4.